State Stem Cell Agency ICOC Legislative Subcommittee Agenda 8/06/09
California State Stem Cell Agency
MEETING NOTICE AND AGENDA
OF THE INDEPENDENT CITIZENS OVERSIGHT COMMITTEE
TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
Organized Pursuant to the
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
1. Call to Order
2. Roll Call
[Members of the Public will be invited to provide testimony before or during consideration of each agenda item. Speakers are asked to limit their testimony to three (3) minutes.]
3. Consideration of response to Little Hoover Commission report on CIRM, including but not limited to items continued from meeting on July 16, 2009. (Items # 6-15 in memo considered July 16, 2009).
4. Consideration of endorsement of public healthcare option as part of national healthcare legislation currently under consideration by the US Congress.
5. Public comment.
THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.
Notice is hereby given that the order of consideration of matters on this agenda may be changed without prior notice.
The California Institute for Regenerative Medicine and its Independent Citizens Oversight Committee, and
any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the
meeting facilities are accessible to persons with disabilities, and providing that this notice and information
given to the Members of the Committee is available to the public in appropriate alternative formats when
requested. If you need further assistance, including disability-related modifications or accommodations,
you may contact Melissa King at the California Institute for Regenerative Medicine at 415-396-9100 no
later than the day prior to the meeting.
Questions or requests for additional information prior to the Independent Citizens Oversight Committee
meeting may be referred to Melissa King at the California Institute for Regenerative Medicine at
firstname.lastname@example.org or 415-396-9100.
This meeting agenda is also available on the website for the California Institute for Regenerative Medicine
Last Modified: April 5, 2017